Current stock page

Financial Data

BSX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareMedical - DevicesScore data as of Sep 4, 2026

BSX

Financial Data
Boston Scientific Corporation
Healthcare· Medical - Devices
AIQ Score
NeutralAIQ Edge 7/10
Low Priority
Above Peers
Score data as of Sep 4, 2026
Last price
$47.80
+$0.85 (+1.81%)
Latest market quote
Momentum44
Value58
Quality67
Risk Resilience46
Sentiment
View financial data

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Sep 6, 2026.

Income statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Revenue$5.44B$5.2B$5.29B$5.07B$5.06B$4.66B$4.56B$4.21B
Gross Profit$3.85B$3.61B$3.94B$3.54B$3.42B$2.95B$2.67B$2.65B
Operating Income
Net Income$907M$1.34B$668M$755M$793M$674M$566M$469M
EPS$0.62$0.9$0.45$0.51$0.54$0.46$0.38$0.32
Cash flow statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Operating Cash Flow$1.47B$348M$1.36B$1.34B$1.29B$541M$1.46B$1B
Capital Expenditure-$195M-$177M-$351M-$181M-$190M-$187M-$293M-$304M
Free Cash Flow$1.28B$171M$1.01B$1.16B$1.1B$354M$1.16B$698M
Net Cash Provided By Operating Activities$1.47B$348M$1.36B$1.34B$1.29B$541M$1.46B$1B
Balance sheet
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Assets$45.22B$44.35B$43.67B$42.71B$41.56B$40.14B$39.4B$38.08B
Total Debt$12.75B$11.13B$0$0$12.15B$11.83B$11.27B$11.39B
Cash And Cash Equivalents
Total Liabilities$20.04B$18.25B$19.2B$19.08B$18.91B$17.69B$17.39B$17.12B
Total Stockholders Equity$25.17B$26.1B$24.47B$23.63B$22.65B$22.45B$22B$20.96B
Key financial metrics
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio17.2117.4352.9147.950.0655.2758.1665.78
P/B ratio2.533.6007.086.716.055.96
P/S ratio11.5917.9126.7528.5631.3831.9628.8729.32
Debt To Equity0.510.43000.540.530.510.54
Free Cash Flow Yield
Financial ratios
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio
P/B ratio2.533.6007.086.716.055.96
P/S ratio11.5917.9126.7528.5631.3831.9628.8729.32
Return On Equity3.64%5.17%0.00%0.00%3.54%3.03%2.60%2.26%
Debt To Equity

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
Pe
19.39
multipleSep 4, 2026
Pb
2.85
multipleSep 4, 2026
Revenue Growth Yoy
4.59
percentSep 4, 2026
EPS Growth Yoy
-31.11
percentSep 4, 2026
Gross Margin
71.16
percentSep 4, 2026
Operating Margin
21.46
percentSep 4, 2026
ROE
14.9
percentSep 4, 2026
ROIC
10.57
percentSep 4, 2026
Debt To Equity
0.51
ratioSep 4, 2026
FCF Yield
5.07
percentSep 4, 2026
Technical indicators
Close
47.8
priceSep 4, 2026
Volume
15,504,234
volumeSep 4, 2026
Rsi14
38.62
indexSep 4, 2026
MACD
-0.07
indexSep 4, 2026
MACD Signal
0.31
indexSep 4, 2026
MACD Histogram
-0.39
indexSep 4, 2026
Adx14
13.59
indexSep 4, 2026
Sma50
46.89
priceSep 4, 2026
Sma200
66.76
priceSep 4, 2026
Atr14
1.8
priceSep 4, 2026
Historical Volatility
0.37
percentSep 4, 2026
Volume Ma20
19,039,166.3
volumeSep 4, 2026
Risk measures
Resilience Score
46
score_0_100Sep 4, 2026
Beta
0.57
ratioSep 4, 2026
Volatility Annual
37.38
percentSep 4, 2026
Max Drawdown
-60.58
percentSep 4, 2026
Sharpe Ratio
-2.08
ratioSep 4, 2026
Var95
-3.25
percentSep 4, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

BSX Financial Data FAQ

What is Boston Scientific Corporation's revenue?

Boston Scientific Corporation's revenue is one of the core financial data points for BSX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Boston Scientific Corporation's revenue growing?

Revenue growth shows whether Boston Scientific Corporation is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is BSX's EPS?

BSX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Boston Scientific Corporation's net income?

Boston Scientific Corporation's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Boston Scientific Corporation generate?

Free cash flow shows how much cash Boston Scientific Corporation generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Boston Scientific Corporation have?

Cash and debt help frame BSX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.